Simponi Golimumab Application Scope

For the treatment of moderate to severe active rheumatoid arthritis in adult patients. For the treatment of active ankylosing spondylitis in adult patients16.Used alone or in combination with methotrexate for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to disease-modifying antirheumatic drugs (DMARDs).

Simponi Golimumab Characteristics

Ingredients: Golimumab
Properties: A human monoclonal antibody that specifically targets and neutralizes tumor necrosis factor-alpha (TNF-α), thereby reducing inflammation and modulating the immune response.
Packaging Specification:
- Prefilled syringe or SmartJect autoinjector.
- Packaged 1 syringe/injector per box
Storage: Store in the refrigerator at 2°C to 8°C (36°F to 46°F).
Expiry Date: Please refer to the expiration date printed on the packaging
Executive Standard: Biological product
Approval Number: China: Drug Registration Certificate Number SJ20170050
Date of Revision: The prescribing information may be updated. Please refer to the latest version provided with the medication.
Manufacturer: Janssen Biotech, Inc.

Guidelines for the Use of Simponi Golimumab

Dosage and Administration:
- Recommended Dose: The recommended subcutaneous dose is 50 mg once a month.
- Administration: For subcutaneous injection only. It is injected into the thigh, abdomen, or upper arm. If a caregiver administers the dose, the upper arm can be used. Rotate injection sites and avoid areas that are tender, bruised, red, scaly, hard, or have scars or stretch marks.
- Missed Dose: If a dose is missed, administer it as soon as possible. Then, schedule the next dose a month after the last administered dose. Consult the prescribing doctor for specific guidance.
Adverse Reactions:
- Common Adverse Reactions: These may include upper respiratory tract infections, increased blood pressure, and reactions at the injection site (such as redness, itching, pain)
- Serious Adverse Reactions: Hypersensitivity reactions, hepatitis B virus reactivation, neurological events, hematological events, and increased risk of certain malignancies have been reported. Close monitoring is essential
Contraindications:
- Patients with clinically significant active infections.
- Patients with known severe hypersensitivity to golimumab or any excipient.
Precautions:
- Monitor for signs and symptoms of infection during and after treatment.
- Screen for tuberculosis prior to initiating therapy.
- Vaccinations should be up to date before starting treatment.
- Use with caution in patients with a history of malignancy.

Simponi Interactions

Concurrent use with other biologic agents or live vaccines is not recommended.
Use with caution when combined with immunosuppressive agents.
Monitor for potential interactions with other medications as per the prescribing information.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.